Protective Effects of cyclosporine and NIM-811 in murine hepatic ischemia-reperfusion injury model

During hepatic surgery or liver transplantation, the liver is vulnerable to ischemia-reperfusion injury (IRI), especially when vessels are compressed to control bleeding or during periods of ischemia. The hallmark of IRI comprises mitochondrial dysfunction, which generates reactive oxygen species, and cell death through necrosis or apoptosis. Cyclosporine (CsA), a well-known immunosuppressive agent that inhibits calcineurin, has the additional effect of inhibiting the mitochondrial permeability transition pore (mPTP), and hence preventing mitochondrial swelling and injury. NIM-811, which is the nonimmunosuppressive analog of CsA, has a similar effect on mPTP.

In this research, NIM-811 served as an important control to identify a comparable effect with CsA, without the immunosuppressive action. Compared with the control mice, the mice treated with 10 and 25 mg/kg of CsA and NIM-811 had significantly lower serum alanine transaminase (ALT) levels. Moreover, the liver tissue showed reduced histological injury scores after treatment with CsA at 2.5, 10, and 25 mg/kg and NIM-811 and significant decrease in apoptosis after treatment with CsA at all doses.

Furthermore, the levels of the pro-inflammatory cytokines, particularly interleukin (IL)-1β, IL-2, IL-4, IL-10, and keratinocyte chemoattractant/human growth-regulated oncogene significantly decreased in the mice treated with the highest dose of CsA (25 mg/kg) than those in the control mice.

The study was published in the KeAi journal Liver Research.

The findings provide evidence that CsA can reduce hepatic warm IRI in a murine model. Similar findings with the use of its nonimmunosuppressive analog NIM-811 suggested that the protection was unlikely mediated by immunosuppressive pathways. Furthermore, these results have potential implications on mitigating IRI during liver transplantation and resection.

###

Contact the author: A.M. James Shapiro, Department of Surgery, Faculty of Medicine & Dentistry, University of Alberta, Edmonton, AB, Canada. E-mail address: jshapiro@ualberta.ca.

The publisher KeAi was established by Elsevier and China Science Publishing & Media Ltd to unfold quality research globally. In 2013, our focus shifted to open access publishing. We now proudly publish more than 100 world-class, open access, English language journals, spanning all scientific disciplines. Many of these are titles we publish in partnership with prestigious societies and academic institutions, such as the National Natural Science Foundation of China (NSFC).